Waverley Pharma Inc.

Equities

WAVE

CA94357L1058

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 02:50:44 2024-07-05 pm EDT			5-day change	1st Jan Change
0.015 ^CAD	0.00%		0.00%	-40.00%

Jun. 20	Waverley Pharma Inc. Elects James Kinley as Director	CI
May. 29	Waverley Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Waverley Pharma Inc Provides Revenue Guidance for the Fourth Quarter and Full Year of 2018

March 11, 2019 at 08:25 am EDT

Waverley Pharma Inc. provides revenue guidance for the fourth quarter and full year of 2018. For the quarter and full year of 2018, the company expected net revenue estimate for the quarter and year ended December 31, 2018 is CAD 200,000.

Latest news about Waverley Pharma Inc.

Waverley Pharma Inc. Elects James Kinley as Director	Jun. 20	CI
Waverley Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 29	CI
Waverley Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
Waverley Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 27	CI
Waverley Pharma Inc. Announces Changes to Board of Directors	Nov. 22	CI
Waverley Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
Waverley Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
Waverley Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
Waverley Pharma Inc. Auditor Raises 'Going Concern' Doubt	23-04-26	CI
Waverley Pharma Provides Business Update	23-03-20	MT
Waverley Pharma Provides Update on PARP-1 Inhibitor Program	23-01-11	MT
Waverley Pharma Inc. Provides Update on its PARP-1 Inhibitor Program	23-01-11	CI
Waverley Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-24	CI
Waverley Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-26	CI
Waverley Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-30	CI
Waverley Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-29	CI
Waverley Pharma Inc. Auditor Raises 'Going Concern' Doubt	22-04-28	CI
Waverley Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-26	CI
Waverley Pharma Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-26	CI
Waverley Pharma Announces Successful Tender Award For Pemetrexed With NHS England	21-05-27	MT
Waverley Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-25	CI
Waverley Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-26	CI
Waverley Pharma Inc. Auditor Raises 'Going Concern' Doubt	21-04-25	CI
Waverley Pharma : Awarded 2-Year Tender For Oncology Drug With NHS Scotland	21-01-18	MT
Waverley Pharma Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-26	CI

Chart Waverley Pharma Inc.

Duration

Period

More charts

Company Profile

Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of human therapeutics focused on oncology. The Company is focused on the generic oncology injectable market in Europe, the United Kingdom (UK), and North America. The Company, through its subsidiaries, has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited, which has granted the Company an exclusive territorial license to market and sell capecitabine in the UK and Germany as well as a non-exclusive territorial license to market and sell temozolomide and erlotinib in the UK. Its generic oncology products include bortezomib and pemetrexed. Bortezomib is an injectable generic chemotherapy drug, developed for the treatment of multiple myeloma and mantle cell lymphoma. Pemetrexed is an injectable generic chemotherapy drug, developed for the treatment of non-small cell lung cancer and pleural mesothelioma.

Sector

Biotechnology & Medical Research

Calendar

2024-08-22 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
WAVERLEY PHARMA INC.	-40.00%	595K
VERTEX PHARMACEUTICALS INCORPORATED	+20.95%	127B
REGENERON PHARMACEUTICALS, INC.	+23.00%	117B
ARGENX SE	+26.84%	27.77B
BIONTECH SE	-19.75%	20.44B
GENMAB A/S	-14.90%	16.62B
BEIGENE, LTD.	-16.56%	15.92B
NEUROCRINE BIOSCIENCES, INC.	+11.19%	14.74B
WUXI APPTEC CO., LTD.	-46.65%	14.94B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs